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Abstract 
 
Following intravenous injection of anti-cancer nanomedicines, many barriers need to be 
overcome en route to the tumor. Cell-mediated delivery of nanoparticles (NPs) is promising in 
terms of overcoming several of these barriers based on the tumoritropic migratory properties 
of particular cell types. This guided transport aims to enhance the NP accumulation in the 
tumor and moreover enhance the infiltration of regions that are typically inaccessible for free 
NPs. Within this study, cytotoxic CD8+ T cells were selected as carriers based on both their 
ability to migrate to the tumor and their intrinsic cytolytic activity against tumor cells. Many 
anti-cancer nanomedicines require tumor cell internalization to mediate cytosolic drug 
delivery and enhance the anti-cancer effect. This proof-of-concept therefore reports on the 
reversible attachment of liposomes to the surface of cytotoxic T lymphocytes via a reduction 
sensitive coupling. The activation status of the T cells and the liposome composition are 
shown to strongly influence the loading efficiency. Loading the cells with liposomes does not 
compromise T cell functionalities like proliferation and cytolytic function. Additionally, the 
triggered liposome release is demonstrated upon the addition of glutathione. Based on this 
optimization using liposomes as model NPs, a small interfering RNA (siRNA)-loaded NP was 
developed that can be coupled to the surface of CD8+ T cells.  
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1 Introduction 
 
Nanoparticles (NPs) have been widely investigated for the delivery of anti-cancer drugs to 
tumor tissues [1-3]. Although a lot of research has been performed, to date, only few 
nanomedicines are in clinical use for the treatment of cancer [4, 5]. One of the key challenges 
is inadequate targeted delivery of drug-loaded NPs to the tumor tissue following systemic 
administration. A critical barrier remains the vascular endothelium which controls the 
extravasation of NPs from the bloodstream into the target tissue [6, 7]. Because NP 
extravasation is dependent on the size of fenestrae, tumor tissue may favor this delivery route 
by its leaky blood vasculature. This increased extravasation in combination with the poor 
lymphatic drainage found in tumors results in the accumulation of NPs in the tumor tissue and 
is also known as the enhanced permeation and retention (EPR) phenomenon [8]. 
Unfortunately, the widespread application of the EPR-based passive targeting of tumors is 
hampered by the heterogeneity in tumor vasculature both within a single tumor and between 
different tumor types [9]. 
Besides relying on passive targeting alone, nanomedicines are frequently modified with a 
targeting ligand that specifically recognizes a receptor that is present on or overexpressed by 
tumor cells. Several studies have shown that this active targeting strategy enhances the 
internalization in the target cells, albeit without increasing the accumulation in the tumor 
tissue after systemic delivery [10-12]. Furthermore, it was observed that active targeting can 
hinder the diffusion of NPs into the tumor tissue due to the binding-site barrier phenomenon 
in which particles mainly bind to perivascular cells [1]. 
One alternative strategy that might overcome these targeting limitations is cell-mediated 
delivery [13, 14]. Certain cell types have the intrinsic ability to cross the endothelial barrier 
and infiltrate the tumor tissue, which makes them attractive carriers for NP delivery [15]. 
Moreover, tumors contain hypoxic and necrotic regions that are typically not easily accessible 
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for NPs, leading to incomplete tumor regression [16, 17]. Monocytes and macrophages have 
already been investigated as carriers for the delivery of NPs in these low accessible regions 
[18-20]. Also T cells have the intrinsic ability to migrate to the tumor tissue. Moreover, 
cytotoxic CD8+ T lymphocytes (CTLs) have the added advantage of exerting a cytotoxic 
effect on tumor cells upon their recognition and binding of tumor-associated antigens. By 
virtue of these specific traits, the adoptive transfer of T cells is a widely investigated cancer 
immunotherapy. Adoptive T cell therapy can be described as the transfer of ex vivo selected 
and expanded tumor-reactive T cells [21]. Although adoptive T cell therapy already showed 
impressive clinical outcomes, complete tumor regression was only observed in a restricted 
number of patients mainly due to the immunosuppressive tumor microenvironment and also 
the loss of tumor antigens to which the therapy was targeted [22, 23]. Therefore, strategies 
combining conventional chemotherapies with cancer immunotherapy have gained interest in 
recent years [24]. 
The use of T cells as NP carrier cells has been assessed previously by Irvine and colleagues, 
who irreversible attached drug-loaded NPs to their surface and also by Vile and co-workers, 
who exploited T cells for the intratumoral delivery of therapeutic viral vectors [25-27]. Here, 
we propose a synergistic strategy based on CTLs that serve a dual purpose, i.e. induce a direct 
killing effect on tumor cells and enhance the delivery of drug-loaded NPs into tumor tissue, 
which may kill T cell-refractory tumor cells. To this end, we investigated the covalent 
attachment of NPs to the surface of CTLs. Moreover, we envisioned the triggered release of 
the cell surface-conjugated NPs in the tumor microenvironment which could allow their 
subsequent internalization by target tumor cells and hence a more efficient delivery of anti-
cancer drugs. This concept is of particular interest for charged macromolecular therapeutics 
that are membrane-impermeable such as small interfering RNA (siRNA), which require NP-
mediated cytosolic delivery in target cells. To date, a reversible coupling strategy of NPs to 
the surface of CTLs has not yet been investigated.  
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Given their outstanding promise and versatility as drug delivery systems, we used liposomes 
as model nanomedicines within this proof-of-concept [28]. First, it was assessed whether 
liposomes can be attached to the surface of CTLs based on disulfide bond formation between 
exofacial thiols present on the CTL plasma membrane and thiol-reactive liposomes. Next, we 
showed the triggered release of liposomes in the presence of glutathione as a reducing agent. 
Importantly, in vitro data indicated that the NP-load did not affect the T cell functionalities 
such as proliferation and cytotoxic effector functions.  
It has been demonstrated that the adoptive transfer of less differentiated T cells is associated 
with superior persistence and anti-tumor responses compared to the more differentiated 
effector T cells [29, 30]. On the other hand, the differentiation of naive T cells into CD8+ 
effector T cells is required for their migratory and cytotoxic function. Since both activated and 
naive T lymphocytes are investigated for adoptive T cell therapy, we therefore evaluated the 
reversible coupling of liposomes as a function of their activation status [31].  
Finally, building further on this optimized reversible coupling strategy, we demonstrated the 
coupling of lipid-enveloped nanogels, loaded with siRNA, to the surface of activated CD8+ T 
cells.  
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2 Materials and Methods 
Preparation of liposomes and characterization: 
The liposomes were composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), egg 
phosphatidylglycerol (egg PG) or 18:1 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[3-
(2-pyridyldithio)propionate] (PE-PDP), and the fluorescent 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine (DiD). DOPC and PE-PDP lipids were purchased from Avanti 
Polar Lipids (Alabaster, AL), PG lipids from Lipoid (Ludwigshafen, Germany), and DiD 
from Molecular probes (Invitrogen, Merelbeke, Belgium). The typical liposome composition 
comprised 50 wt% PE-PDP or PG, 3 wt% DiD, and 47 wt% DOPC. When varying the PE-
PDP or PG content, the fraction of DOPC lipids was adjusted accordingly. To form the 
liposomes, a lipid mixture in chloroform was prepared and pipetted in a round-bottom glass 
flask, followed by evaporation of the chloroform solvent to form a thin lipid film. The dried 
lipids were rehydrated in phosphate buffered saline (PBS; Gibco-Invitrogen, Merelbeke, 
Belgium) at ambient temperature followed by an extrusion of the resultant multilamellar 
liposomes through a 200 nm polycarbonate filter (Whatman, Diegem, Belgium). Liposome 
size and surface charge were measured in HEPES buffer (20 mM, pH 7.4) at 25 °C by 
dynamic light scattering and zeta potential measurements, respectively, using a Zetasizer 
Nano ZS (Malvern, UK) equipped with Dispersion Technology Software (DTS).  
Cell culture: 
CD8+ T cells were isolated from the spleen of OT-I mice using a negative isolation CD8+ kit 
(stem cell technologies, Grenoble, France). Cells were activated with anti-CD3/CD28 
Dynabeads® (Gibco-Invitrogen) at a density of 2 x 106 cells/well and a bead-to-cell ratio of 
1:1 in a 24-well plate. The cells were cultured in complete T cell culture medium containing 
advanced RPMI medium (Gibco-Invitrogen) supplemented with 10% fetal bovine serum 
(FBS; Hyclone, Thermo Scientific, MA, USA), 2 mM L-glutamine (Gibco-Invitrogen), 1% 
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penicillin/streptomycin (Gibco-Invitrogen). According to the manufacturer’s protocol 
30 U ml-1 rIL-2 (Miltenyi Biotec, Leiden, The Netherlands) was added to the culture medium 
and restimulation was performed by adding new beads every 7 days.  
The mouse thymoma cell lines EL4 and E.G7-OVA were purchased from the American Type 
Culture Collection (ATCC). The E.G7-OVA cell line is an EL4 cell line that was stably 
transfected with the plasmid pAc-neo-OVA, which carries a complete copy of chicken 
ovalbumine (OVA) mRNA. Both cell lines were cultivated in RPMI 1640 (Gibco-Invitrogen) 
supplemented with 10% FBS, 2 mM L-glutamine, and 1% penicillin/streptomycin. 
Visualization of exofacial thiol groups: 
CD8+ T cells were incubated for 15 min with 100 µg ml-1 Cy5-labeled maleimide (GE 
Healthcare Life Sciences, Diegem, Belgium) at room temperature. After washing the cells 
with PBS, the cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, Bornem, 
Belgium). Confocal microscopy images were acquired using a Nikon C1si confocal laser 
scanning microscope (Nikon Benelux, Brussels, Belgium) equipped with a Plan Apo VC 60x 
1.4 NA oil immersion objective lens (Nikon). The Cy5 dye was excited with a 636 nm diode 
laser (CVI Melles Griot, NM, USA). 
Reversible coupling of liposomes to the surface of CD8+ T cells: 
CD8+ T cells (3 x 105 cells per sample) were incubated in serum-free advanced RPMI with 
the liposomes during 1h at 37 °C with gentle mixing after 30 min. A liposome concentration 
of 2 mg ml-1 lipids was used, if not indicated differently. Subsequently, the cells were washed 
with PBS (supplemented with 5% FBS) and to discriminate the CD8+ population the cells 
were stained with a CD8-AlexaFluor488 antibody (BD Pharmingen, Erembodegem, Belgium) 
for 30 min at room temperature in PBS (supplemented with 5% FBS). The amount of 
liposomes attached to the CD8+ T cells was quantified via flow cytometry by measuring the 
DiD (red) fluorescence intensity per cell. In addition, a dead cell stain was performed by 
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incubating the (liposome-loaded) cells with 60 nM SYTOX® green nucleic acid stain 
(Molecular Probes) for 15 min at room temperature in PBS (supplemented with 5% FBS). The 
viable population was identified and selected based on the SYTOX® green stain. The 
activation status of the T cells was evaluated with a phycoerythrin (PE)-labeled CD25 
antibody (BD Pharmingen).  
To evaluate the detachment of the liposomes from the T cell surface, the liposome-loaded 
cells were incubated with mounting concentrations of glutathione (Sigma-Aldrich) for 30 min 
at 37 °C. The glutathione dilutions were prepared in PBS (supplemented with 5% FBS) and 
the pH was adjusted to physiological pH. After incubation, the released liposomes were 
removed by washing the cells in PBS (supplemented with 5% FBS) and the remaining DiD 
fluorescence per CD8+ T cell was quantified by flow cytometry. Flow cytometry data were 
acquired by a FACSCalibur™ (BD Pharmingen) and analyzed using BD CellQuest™ and 
FlowJo (Treestar Inc, Ashland, USA) software. 
Characterization of detached liposomes by fluorescence single particle tracking (fSPT): 
CD8+ T cells were first incubated with PDP-functionalized liposomes that were fluorescently 
labeled with DiD as described in the previous section, followed by two washing steps with 
PBS to remove the unbound particles. Subsequently, the cells were incubated with 2 mg ml-1 
glutathione during 30 min at 37 °C. After centrifugation of the cells, the supernatant was 
collected and analyzed by fSPT. The latter technique enables the measurement of the size of 
NPs in biological fluids by recording the movement of fluorescently labeled particles. The 
DiD fluorophores in the liposomes were excited by swept-field laser illumination (100 mW 
Spectra Physics Excelsior 642 nm, CA, USA) on an epi-fluorescent microscope (Eclipse T, 
Nikon BeLux, Brussels, Belgium) equipped with a Plan Apo VC 100x 1.4 NA oil immersion 
objective lens (Nikon). The diffusion of individual liposomes was recorded in high-speed 
movies by a fast and sensitive CCD camera (Ixon Ultra 897, Andor Technology, CT, USA). 
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The motion trajectories of single particles were obtained by in-house developed software. 
Subsequently, the diffusion coefficient for each trajectory was calculated and transformed in a 
size distribution using the Stokes-Einstein equation. Data were further refined by the maximal 
entropy deconvolution method, as described by our group previously [32]. 
Visualization of T cell surface-conjugated liposomes by confocal microscopy: 
DiD-labeled liposomes were conjugated to the cell surface of CD8+ T cells as previously 
described, followed by a cell nucleus stain with 10 µg ml-1 Hoechst 33342 (Molecular Probes) 
and a CD8-AlexaFluor488 antibody stain (BD Pharmingen). The dyes were respectively 
excited by a 636 nm diode laser, a 408 nm diode laser, and a 488 nm argon-ion laser (all 
purchased from CVI Melles Griot). Images were recorded with a Plan Apo VC 60x 1.4 NA 
oil immersion objective lens (Nikon).  
T cell proliferation assay: 
CD8+ T cells activated during 9 days were first stained with 7.5 µM CFSE (Life Technologies, 
Merelbeke, Belgium) and subsequently conjugated with DiD-labeled liposomes as previously 
described. The proliferation of the T cells was then measured by the dilution of the CFSE 
stain over the daughter cells with flow cytometry at varying time points (0h, 24h and 48h) 
after loading. The distribution of the liposomes over the daughter cells was determined by 
measuring the DiD fluorescence intensity per cell. During the experiment, the activated cells 
were incubated in cell culture medium supplemented with 30 U ml-1 rIL-2.  
In vitro cytotoxic T cell (CTL) assay: 
EL4 and E.G7-OVA cells were stained with 5 µM and 15 µM CFSE stain, respectively. The 
OT-I CTLs were activated for 9 days with anti-CD3/CD28 Dynabeads® and incubated with 
PDP-functionalized liposomes at a concentration of 5 mg ml-1 lipids, followed by two 
washing steps to remove unbound particles. Subsequently, the OT-I T cells were co-cultured 
with EL4 and E.G7-OVA cells at two different effector-to-target ratios. To increase cell 
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contact between T cells and target cells, the incubation was performed in a U-bottom 96-well 
plate (Falcon, BD Biosciences) in complete T cell culture medium. After 4h at 37 °C the ratio 
of EL4 cells compared to E.G7-OVA cells was quantified by flow cytometry, in which the 
viable population was selected based on forward scatter/side scatter and both cell lines could 
be distinguished by their different CFSE fluorescence intensity signal. 
 
Coupling of siRNA-loaded nanoparticles to CD8+ T cells: 
Our group has developed biodegradable dextran nanogels (NGs) via an inverse mini-emulsion 
photopolymerization of dextran hydroxyethyl methacrylate (dex-HEMA) in mineral oil. To 
incorporate cationic charges in the nanoscopic hydrogel network, cationic methacrylate 
monomers ([2-(methacryloyloxy)-ethyl]trimethylammonium chloride, TMAEMA, Sigma-
Aldrich) were copolymerized with dex-HEMA [33]. Recently, experimental evidence was 
provided that these siRNA-loaded NGs (siNGs) can efficiently be coated with a lipid bilayer 
[34]. Here, the NGs were first loaded with 5 pmol AlexaFluor488-labeled siRNA 
(Eurogentec, Seraing, Belgium) per µg NGs. Next, the siNGs were layered with a lipid 
mixture composed of 50 wt% PE-PDP, 3 wt% DiD, and 47 wt% DOPC. Briefly, the siNGs 
were incubated for 10 min at 4°C with the hydrated lipid mixture, allowing electrostatic 
interaction, applying 10 mg lipid per mg NGs. After incubation, the lipid coat was formed by 
high-energy sonication using a probe sonicator (amplitude 10 %, Branson Digital Sonifier®, 
CT, USA). The lipid-coated siNGs were separated from excess lipids by centrifugation 
through a 7.5 wt% OptiPrepTM (Sigma-Aldrich) cushion for 30 min at 30000 g (L8-70M 
Centrifuge with SW55 Ti rotor; Beckman Coulter, Suarlée, Belgium). The supernatant, 
containing empty lipid vesicles, was discarded. The resulting pellet, containing the purified 
lipid-coated siNGs, was resuspended in nuclease-free water. Subsequently, equal volumes of 
the resuspended formulation and double-concentrated PBS were mixed, in order to obtain 
physiological salt concentrations. Using this protocol, lipid-coated siNGs were obtained with 
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a hydrodynamic diameter around 400 nm as analyzed using fluorescence single particle 
tracking (fSPT) [35]. 
The lipid-coated siNGs (0.25 mg ml-1 NG) were incubated with 3 x 105 CD8+ T cells (9 days-
activated) for 45 min at 37°C in serum-free advanced RPMI. Cells were washed with PBS 
(supplemented with 5% FBS). The amount of lipid-coated siNGs per cell was quantified by 
flow cytometry and visualized by confocal microscopy, as previously described. Flow 
cytometry data were acquired by a CytoFLEX (Beckman Coulter) and analyzed using FlowJo 
software. 
 
Quantifying siRNA release via fluorescence fluctuation spectroscopy: 
Fluorescence fluctuation spectroscopy (FFS) is a microscopy-based technique that monitors 
fluorescence intensity fluctuations in the excitation volume of a confocal microscope. 
Fluorescence fluctuations originate from the diffusion of fluorescent molecules in and out the 
excitation volume. To calculate the percentage free siRNA in the formulation, a fluorescence 
baseline of free siRNA molecules was recorded and compared with the baseline of the 
complexed siRNA. Upon encapsulation in NPs, the fluorescence baseline of the siRNA 
molecules will drop, from which the loading efficiency can be calculated as described earlier. 
As was shown by our group, the complexation of siRNA molecules in NPs can be determined 
in different media including full human serum [35]. Within this study, the siRNA release from 
the non-coated versus lipid-coated siNGs was measured in the presence of competing 
polyanions such as dextran sulfate (DEXS; 10kDa; 2.5 mg ml-1; Sigma-Aldrich) and human 
serum (obtained from a healthy donor and stored at -20°C). Equal volumes of serum or the 
competing polyanions in HEPES buffer were mixed with the siNGs and incubated for 10 min 
at room temperature before transferring to a glass-bottom 96 well-plate for FFS analysis 
(Greiner Bio-One GmbH, Frickenhausen, Germany). Measurements were performed with a 
Nikon C1si confocal laser scanning microscope (Nikon Benelux) equipped with a Plan Apo 
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60x 1.2 NA water immersion objective lens (Nikon), using a 488 nm argon-ion laser (CVI 
Melles Griot) This setup was combined with the detection channels of a fluorescence 
correlation spectrometer MicroTime 200 (Picoquant GmbH, Berlin, Germany) equipped with 
SymPhoTime software. Fluorescence fluctuations were recorded during 1 min. 
Statistical analysis: 
A two-tailed Student's t-test was performed to determine statistical differences between 
datasets. All statistical analyses were performed using GraphPad Prism 6 software (La Jolla, 
CA, USA). p-values <0.05 were regarded significant. Statistical significance is indicated as 
follows: **p <0.01; ***p < 0.001; ****p < 0.0001. 
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3 Results 
3.1 Liposomes for reversible attachment to cytotoxic T lymphocytes 
Within this study liposomes were selected as model nanoparticles (NPs) to optimize 
reversible coupling to cytotoxic T lymphocytes (CTLs). Varying amounts of thiol-reactive 
phospholipids, carrying a pyridyldithiopropionate (PDP) head group, were incorporated in the 
liposome bilayer, next to DOPC lipids. The PDP moiety can form a reducible disulfide bond 
with the thiol groups exposed at the cell surface (exofacial thiols), allowing the reversible 
covalent coupling of the liposomes (Figure 1A) [36]. Importantly, PDP-functionalized lipids 
(PE-PDP lipids) contain a negative charge that may interact with cationic regions at the 
plasma membrane, thereby possibly causing nonspecific binding [37]. To account for these 
nonspecific interactions, the cellular attachment of control liposomes, in which the PDP-
functionalized lipids were replaced by the negatively charged phosphatidylglycerol (PG) 
lipids, was evaluated in parallel. Both PDP and PG liposomes have a similar hydrodynamic 
diameter (~150 nm) and zeta potential, of which the latter depends on the liposomal 
composition. For instance, when 50 wt% PDP or PG lipids were incorporated, a mean zeta 
potential value around -65 mV was measured. Whenever other compositions were used, their 
respective zeta potential values are indicated in a table additional to the experimental data.  
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Figure 1. (A) Schematic representation of the formation of a disulfide bond between PDP-
functionalized lipids that are incorporated into the liposome bilayer and reduced exofacial 
thiol groups, present at the cell surface. (B) Transmission and confocal fluorescence images of 
non-activated murine OT-I CD8+ T cells incubated with Cy5-labeled maleimide. 
 
3.2 Reversible coupling of liposomes to the surface of non-activated CD8+ T cells 
Murine OT-I CD8+ T cells, which are genetically engineered to express a T cell receptor 
(TCR) against ovalbumine (OVA), were selected as carriers for the cell-mediated delivery of 
the liposomes. To allow the formation of a disulfide bond between free thiol groups at the 
CTL plasma membrane and PDP liposomes, we first assessed the availability of free thiol 
groups at the CD8+ T cell surface by incubating them with Cy5-labeled maleimide [36]. The 
maleimide group can interact with thiol groups to form a stable thioether bond. Confocal 
images clearly demonstrated the presence of thiol groups that appeared to be uniformly 
distributed over the entire cell surface (Figure 1B). 
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3.2.1 Attachment of liposomes to the surface of non-activated CD8+ T cells 
Isolated CD8+ T cells from the spleen of OT-I mice were incubated with fluorescently labeled 
(DiD) liposomes and the amount of liposomes coupled to the cell surface was quantified by 
flow cytometry. We first determined the fraction of PDP lipids that needs to be incorporated 
into the liposomal membrane to achieve efficient binding. To this end, the cells were 
incubated with liposomes containing increasing amounts of PDP lipids, ranging from 10 to 
50 wt%. Cells were incubated with a 2 mg ml-1 lipid concentration as we determined that a 
higher concentration only results in a moderate increase in cellular attachment (Figure S1). 
To quantify nonspecific interactions, the cellular binding of PG liposomes with PG lipid wt% 
also ranging from 10 to 50, was determined in parallel. It was verified that both PDP and PG 
liposomes have equivalent zeta potentials (Figure 2A). As displayed in Figure 2B, the 
nonspecific binding was independent of the liposomal composition. Strikingly, only 
liposomes composed of 50 wt% PDP-modified lipids showed specific binding to the T cells, 
accompanied by a more than three-fold difference in mean fluorescence intensity per cell 
between PG and PDP liposomes for this composition. Hence, further experiments were 
performed with liposomes carrying 50 wt% PDP-functionalized or PG lipids.  
The presence of fluorescently labeled liposomes at the surface of the CD8+ T cells was 
visualized by confocal microscopy. The images depicted in Figure 2C show localized bright 
fluorescent spots at the T cell surface, contrary to the free thiol staining with Cy5-labeled 
maleimide that showed a more uniform distribution (Figure 1B). Of note, from these images 
it is evident that the liposomes are indeed predominantly anchored to the surface of the cells 
and not internalized, confirming previous reports [25, 38]. 
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Figure 2. The reversible coupling of DiD fluorescently labeled liposomes to the surface of 
non-activated OT-I CD8+ T cells. (A) Zeta potential measurements of the different liposome 
compositions. (B) CD8+ T cells were incubated with PG and PDP liposomes with increasing 
wt% PG and PDP lipids as indicated in the graph. Data represent DiD mean fluorescence 
intensity (MFI) per cell ± SD (n = 2). (C) Confocal overlay image (left) and red channel 
(right) of T cells incubated with AlexaFluor488-labeled anti-CD8 antibodies (green), Hoechst 
cell nucleus stain (blue), and DiD-labeled liposomes (red) (Scale bar = 5 µm). (D) Decrease in 
DiD MFI after incubation of the cells with increasing concentrations of glutathione. Data 
represent MFI ± SD (n = 3; ns = not significant; *** = p<0.001; **** = p<0.0001).  
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3.2.2 Triggered detachment of liposomes from the cell surface of non-activated CD8+ T 
cells. 
Having established the optimal liposome composition, we next sought to evaluate whether the 
liposomes can be detached again from the cell surface. We anticipated that incubating the 
liposome-loaded T cells with reducing agents such as glutathione can cause a thiol-disulfide 
exchange reaction, resulting in the release of the disulfide-bound liposomes from the T cell 
surface [39]. To explore the latter, the liposome-loaded CD8+ T cells were incubated with 
mounting concentrations of glutathione. As depicted in Figure 2D, an increase in the 
glutathione concentration was associated with a decrease in the amount of attached DiD-
labeled PDP liposomes, indicative of their triggered release. Upon incubation with 2 mg ml-1 
glutathione, a release of 60% of the attached particles was observed.  
 
3.3 Reversible coupling of liposomes to the surface of activated CD8+ T cells 
Given that activated T cells outperform their non-activated counterparts in terms of tumor 
migratory capacity and cytolytic activity, we next aimed to assess the impact of T cell 
activation on the covalent coupling of liposomes. For this purpose, murine OT-I T cells were 
activated using anti-CD3/CD28 Dynabeads®. The activation status was evaluated by the 
expression of the IL-2 receptor CD25, which is up-regulated after stimulation [40]. 
3.3.1 Attachment of liposomes to the surface of activated CD8+ T cells 
Similar to the attachment of liposomes to the surface of non-activated T cells, the coupling of 
liposomes to activated CD8+ T cells was first quantified as a function of wt% incorporated 
PDP lipids. The zeta potential data from the different liposome compositions were represented 
in Figure 3A. In accordance with the results on non-activated CD8+ T cells, we again 
observed a significant specific binding only for the liposomes with 50 wt% PE-PDP lipids 
incorporated (Figure 3B). Thus, also for the activated T cells this composition was selected 
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for further investigation. To evaluate the maximal coupling, the cells were incubated with 
increasing liposome concentrations. A sharp increase in cell binding was observed from 0.1 to 
1 mg ml-1 lipids while a further increase up to 10 mg ml-1 only resulted in a moderate 
improvement of the coupling (Figure 3C). In analogy with non-activated T cells, liposomes 
bound to activated T cells also remain localized at the cell surface in distinct foci, as verified 
with confocal microscopy (Figure 3D).  
 
 
Figure 3. The coupling of DiD fluorescently labeled liposomes to the surface of 
activated OT-I CD8+ T cells, activated with anti-CD3/anti-CD28 Dynabeads® during 
10 days. (A) Zeta potential measurements of the different liposomal compositions. (B) 
CD8+ T cells were incubated with 2 mg ml-1 PG and PDP liposomes with increasing 
amounts of PG and PDP lipids as indicated. Data represent the mean fluorescence 
intensity (MFI) of DiD per cell ± SD (n = 3). (C) Binding of DiD-labeled liposomes to 
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CD8+ T cells as a function of lipid concentrations. Data represent DiD mean fluorescence 
intensity (MFI) per cell ± SD (n = 3). (D) Confocal images of T cells incubated with 
AlexaFluor488-labeled anti-CD8 antibodies (green), Hoechst cell nucleus stain (blue), and 
DiD-labeled liposomes (red) (Scale bar = 5 µm). 
 
3.3.2 Attachment of liposomes as a function of T cell activation status 
During the activation process CD8+ T cells undergo phenotypic changes such as up-regulation 
of multiple surface markers like CD25, as represented in Figure 4A, and a marked increase in 
size (Figure S2). To address whether these changes influence the attachment of particles to 
the cell surface, CD8+ T cells were activated with anti-CD3/CD28 Dynabeads® over a two-
week time period and the specific coupling of liposomes was quantified at different activation 
time points (Figure 4A). In accordance with the manufacturer’s protocol, the cells were 
restimulated with new Dynabeads® on day 7 of activation. 
In general, a significantly higher attachment of PDP-functionalized liposomes to activated 
cells was observed compared to the non-activated T cells. In analogy with previous 
experiments, PG liposomes were incubated with the T cells as a control for nonspecific 
binding. Here, a similar trend in T cell binding was detected, albeit with markedly lower 
fluorescence intensity. Furthermore, the expression of the CD25 surface marker strongly 
increased from day 7 to day 10 following activation, indicative of an improved T cell 
activation efficiency upon a second activation step with anti-CD3/CD28 Dynabeads® on day 
7. In contrast, when exceeding 10 days of activation again a gradual decrease in CD25 
expression was observed. Importantly, the efficiency of liposome coupling to the T cells 
perfectly correlates with the CD25 expression levels, also reaching optimal specific liposome 
attachment to the T cell surface at day 10 of activation.  
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Figure 4. Reversible coupling of liposomes to the surface of OT-I CD8+ T cells as a 
function of their activation status. (A) Attachment of DiD-labeled PG or PDP liposomes 
(50 wt% PG/PDP – 2 mg ml-1) to the surface of activated CD8+ T cells after the indicated 
days of activation. CD25 expression was quantified as a marker for T cell activation. Data 
represent the mean fluorescence intensity (MFI) per cell ± SD from both DiD labeled 
liposomes (PG and PDP) and PE-labeled CD25 antibody staining (n = 4). (B) PG and PDP 
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liposomes were attached to the surface of the cells, followed by an incubation step with or 
without 2 mg ml-1 glutathione. Data represent the DiD mean fluorescence intensity (MFI) per 
cell ± SD (n = 3; ns = not significant; **** = p<0.0001). (C) Fluorescence single particle 
tracking (fSPT) size distribution of PDP liposomes both before T cell coupling and after 
triggered release from the T cell surface with glutathione. 
 
3.3.3 Triggered detachment of liposomes from the cell surface of activated CD8+ T cells 
To verify that the coupling of PDP liposomes to the surface of activated T cells was indeed 
reversible, the release of liposomes from the surface was evaluated by incubating the 
activated and liposome-loaded CD8+ T cells with glutathione. In accordance with the data 
obtained from non-activated T cells, the glutathione concentration was fixed at 2 mg ml-1. 
Glutathione was able to release ~50% of the PDP liposomes from the CD8+ T cells surface, 
while the DiD fluorescence per cell for the nonspecifically bound PG liposomes remained 
unaffected (Figure 4B). Confocal images of cells incubated with or without glutathione are 
represented in Figure S3. 
To determine whether the released liposomes still have the required size to allow subsequent 
internalization by target cells, we analyzed the size of the detached particles in the 
extracellular medium by fluorescence single particle tracking (fSPT). This technique is a 
microscopy-based method in which fluorescently labeled particles are illuminated by laser 
light and the Brownian motion of the particles is recorded by a fast and sensitive EMCCD 
camera. Based on the trajectories of single particles, calculated from the recorded movies by 
specialized algorithms, the diffusion coefficient and hence the hydrodynamic size of the 
moving particles can be determined, even in complex biological fluids [32]. A comparison 
was made between the liposomes prior to the T cell coupling and the liposomes collected after 
detachment from the T cell surface with glutathione. The average initial liposome size of 
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178 nm, as measured by fSPT, is comparable with a diameter of 150 nm obtained with DLS. 
The liposomes that were released from the T cell surface in the presence of glutathione have a 
slightly increased average diameter (228 nm), which remains within an acceptable size range 
for subsequent endocytosis by tumor cells (Figure 4C). 
 
3.4 Influence of cell surface-attached liposomes on T cell functionalities 
3.4.1 Proliferation of CD8+ T cells after coupling of liposomes 
Proliferation is one of the key cellular functions of T cells upon activation. We therefore 
sought to evaluate whether the proliferative capacity of the cells could be compromised at the 
highest achievable liposome-conjugation in this study. The proliferation of T cells was 
determined by staining the activated T cells with CFSE and following the subsequent dilution 
of this stain over the daughter cells as a function of cell division. To this end, the cells were 
first incubated with a high concentration of 50 wt% PDP liposomes (20 mg ml-1 lipid 
concentration) for which a maximal coupling is expected (Figure 3). For the untreated T 
cells, a clear decrease in CFSE fluorescence intensity could be observed over time, reflecting 
CFSE dilution by T cell division. Importantly, T cells carrying a maximal amount of PDP 
liposomes on their surface also maintained a normal proliferative behavior (Figure 5A). 
Furthermore, the cell surface-attached liposomes were equally distributed over the daughter 
cells during cell division as was demonstrated by the simultaneous dilution of the DiD 
fluorescent signal per cell, albeit with all cells still positive for DiD after 48h (Figure 5B). 
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Figure 5. Proliferation of OT-I CD8+ T cells after liposome coupling to the cell surface. 
CD8+ T cells were first labeled with CFSE and incubated with a high concentration of 50 wt% 
PDP liposomes labeled with DiD (20 mg ml-1 lipids), followed by the incubation over 24h and 
48h within cell culture medium supplemented with 30 U ml-1 rIL-2. (A) Flow cytometry 
histograms representing the CFSE fluorescence intensity and (B) liposomal DiD fluorescence 
intensity per T cell for both liposome-loaded (solid line) and non-loaded cells (dotted line) at 
the start of incubation (black line), after 24h (dark gray line), and after 48h (light gray line). 
 
3.4.2 Cytotoxic T cell effector function after coupling of liposomes 
CTLs are designed to specifically kill target tumor cells. To evaluate whether the anchoring of 
liposomes to the surface of CD8+ T lymphocytes affects their cytotoxic function, OT-I T 
lymphocytes were used that have a TCR recognizing an ovalbumine (OVA)-derived peptide. 
Co-culturing of OT-I T cells with E.G7-OVA lymphoma cells that present this OVA-peptide 
in MHC class I, would result in TCR-mediated killing of the E.G7-OVA cells. Isogenic yet 
OVA negative EL4 cells were included in the co-culture experiment as a control for the 
specificity of this interaction. To discriminate both cell types, EL4 and E.G7-OVA cells, were 
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stained with a low and high concentration of CFSE, respectively. The CFSE-labeled EL4 and 
E.G7-OVA cells were mixed in equal amounts followed by the addition of the OT-I T cells in 
an effector:target (E:T) ratio of 1:1 and 1:20 as indicated in Figure 6. A schematic of this 
experiment is represented in supplementary Figure S4.  
At a 1:1 effector:target ratio the OT-I T cells were able to lyse the majority of the E.G7-OVA 
population in contrast to the EL4 cells that remained unaffected, reflecting the specificity of 
the CTL effector function assay. Notably, Figure 6B clearly demonstrates that the covalent 
attachment of liposomes to the T cell surface does not interfere with their cytotoxic function 
as both liposome-loaded and non-loaded T cells killed 72% of the E.G7-OVA population. To 
exclude the possibility that this E:T ratio was too high and could therefore obscure the 
inhibitory effect of the conjugated liposomes, the co-culture experiment was repeated at a 
suboptimal E:T ratio of 1:20. Although the killing effect of the E.G7-OVA cells obtained at 
the 1:20 ratio is strongly reduced with only 6% lysis compared to 72% for the 1:1 ratio, again 
the attachment of liposomes to the T cell surface did not affect target cell lysis (Figure 6C). 
Quantitative data of this CTL assay are represented in Figure S5. 
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Figure 6. Co-culture of (liposome-loaded) OT-I CD8+ T cells with E.G7-OVA 
target cells and EL4 control cells. (A) E.G7-OVA cells and EL4 cells were labeled 
with a high and low CFSE concentration, respectively. Both cells were mixed in equal 
amounts and incubated for 4h at 37 °C without T cells (gray fill), with non-loaded T 
cells (dotted line), and with liposome-loaded (5 mg ml-1 lipids) T cells (solid line). 
Cells were mixed in both a (B) 1:1 effector:target (E:T) ratio and a (C) 1:20 E:T ratio.  
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3.5 Coupling of siRNA-loaded nanoparticles to CD8+ T cells 
Next, a drug-loaded nanoparticle was developed for anchoring to the surface of CD8+ T cells, 
exploiting our previously optimized coupling protocol. As a therapeutic agent we selected 
small interfering RNA (siRNA), which needs to be delivered into the cytosol of target cells to 
activate gene silencing. However, as the PDP-liposomes are negatively charged they do not 
allow loading of siRNA based on electrostatic interaction. To this end, our research group 
recently developed a hybrid core-shell formulation, in which siRNA is pre-loaded in a 
biodegradable cationic nanogel (NG) core that is subsequently coated with a negatively 
charged lipid shell [34]. Here, we modified this nanocomposite formulation using PDP-
liposomes to construct the outer lipid shell and to enable subsequent coupling of the siRNA-
loaded nanogels (siNGs) to the CD8+ T cell surface.  
Following incubation of this core-shell formulation with activated CD8+ T cells, we could 
demonstrate their coupling to the T cell surface. In Figure 7A, confocal images show the 
coupling of double-labeled PDP lipid-coated siNGs to CD8+ T cells, in which the green-
labeled siRNA (AlexaFluor488) perfectly co-localizes with the red-labeled (DiD) lipid coat. 
In addition, flow cytometry plots indicated that all T cells were loaded with the lipid-coated 
siNGs as the fluorescent signals of both labeled siRNA and lipids are closely correlated 
(Figure 7B). During the coating procedure of the siNGs with the highly anionic PDP-
liposomes a small fraction (~10%) of siRNA was released from the NG core. Importantly, 
Figure 7C shows that the lipid coat offers ample protection against siRNA decomplexation in 
the presence of high concentrations of competing polyanions and in human serum, which 
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indicates the successful deposition of a protective lipid shell around the siNG core. 
 
Figure 7. The coupling of siRNA-loaded nanoparticles to the surface of CD8+ T cells. 
Nanogels (NGs) were first loaded with 5 pmol of AlexaFluor488-labeled siRNA per µg NG 
(siNGs), followed by coating with a lipid layer composed of 50 wt% PE-PDP, 3 wt% DiD, 
and 47 wt% DOPC. Following purification, the lipid-coated siNGs were incubated with 
activated CD8+ T cells. (A) Confocal images of lipid-coated siNGs coupled to CD8+ T cells 
via a disulfide binding. siRNA molecules were labeled with AlexaFluor488 (green) and the 
lipid coat was labeled with DiD (red). (B) Flow cytometry plots representing CD8+ T cells 
incubated with or without lipid-coated siNGs. (C) Influence of the lipid coat on the siRNA 
release in the presence of competing polyanions such as 2.5 mg ml-1 dextran sulfate (DEXS) 
and human serum measured by fluorescence fluctuation spectroscopy. Data represent mean % 
siRNA release ± SD (n = 3; ** = p<0.01; *** = p<0.001). 
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4 Discussion 
The primary goal of this study was to investigate whether liposomes can be reversibly 
attached to the surface of cytotoxic T cells (CTLs). To this end, we exploited the presence of 
thiol groups naturally present on the surface of cells (exofacial thiols) to covalently couple 
liposomes that are equipped with thiol-reactive PDP groups through the formation of a 
disulfide bond. Our results clearly demonstrate that the surface of the T cells can be 
conjugated with high amounts of liposomes. Although the exofacial thiol groups appear to be 
uniformly distributed over the plasma membrane, as evaluated with Cy5-maleimide, confocal 
microscopy imaging revealed a more speckled distribution profile for the liposomes which is 
in agreement with previous observations by Irvine and colleagues [38]. It is conceivable that 
only a fraction of the exposed thiols at the cell surface is accessible for thiol-reactive 
nanoparticles (NPs) in contrast to small molecules which are less prone to steric hindrance. 
Another important observation is the need to incorporate a substantial fraction (50 wt%) of 
thiol-reactive lipids in the liposomal formulation to achieve a significant and specific cell 
surface binding, both for activated and non-activated T cells. We hypothesize that the 
presence of high amounts of thiol-reactive lipids could anchor a single liposome to the T cell 
surface via multiple disulfide bonds, thereby rendering the coupled liposomes more resistant 
to the various washing steps and disulfide cleavage possibly occurring at the cell surface by 
thioredoxins and oxidoreductases that initiate thiol-disulfide exchanges [41, 42]. Our study 
also revealed the importance of the activation status of the T cells toward liposomal coupling. 
We could demonstrate a five-fold increase in the attachment of liposomes for T cells activated 
during 10 days versus non-activated T cells. Further, it was also shown that the attachment of 
liposomes was strongly correlated with the CD25 receptor expression, as a marker of the T 
cell activation status. Likely, the enlargement of the cells upon activation is responsible for 
this higher coupling efficiency, given that the concomitant increase in accessible plasma 
membrane surface will expose more exofacial thiols per cell. Hence, dramatic differences in 
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cell surface-conjugated liposomes could be observed at different activation time points. 
Besides the increase in size, also the up-regulation of various surface proteins, bearing 
cysteine-rich extracellular domains, upon activation of the T cells could influence the 
liposome coupling efficiency. To attain a maximal drug load per T cell, it thus seems more 
appropriate to employ activated cells instead of naive T cells for the attachment of liposomes. 
Although it is recommended in adoptive T cell therapy to use less differentiated T cells, naive 
T cells still require ex vivo activation prior to systemic administration to be able to migrate to 
the tumor site. However, T cell proliferation upon activation results in the rapid division of 
the surface-conjugated liposomes over the daughter cells as shown in the proliferation assay. 
Considering the proliferation during the time needed for T cells to migrate and accumulate in 
the tumor (~24-72h) together with the lower surface liposome-loading, cell-mediated 
liposome delivery using naive T cells will likely result in a lower accumulation of drug-
loaded liposomes at the tumor site [15, 43]. Importantly, the T cells loaded with the maximum 
amount of liposomes retain their capacity to proliferate in vitro while dividing their liposome 
cargo over the daughter cells. Furthermore, even when a suboptimal effector-to-target ratio 
was tested, a similar cytotoxic effect against target tumor cells was observed between 
liposome-loaded and non-loaded T cells. As was observed by confocal imaging, the 
liposomes only occupy a limited amount of the cell membrane, likely not influencing the 
interaction with target cells.  
Within this study, the reducing agent glutathione was selected as a tumor-specific trigger for 
subsequent liposome detachment from the T cell surface. Indeed, glutathione levels are low in 
the circulation and extracellular fluids while elevated levels can be found inside cells, thus 
avoiding premature liposome release [44]. On the other hand, the tumor microenvironment 
typically shows increased thiolytic activity, originating from the release of glutathione by 
dead cells and the overexpression of thiolytic proteins such as thioredoxin, enabling the 
uncoupling of disulfide-linked NPs in the direct vicinity of tumor cells [45]. In the presence of 
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glutathione, 50-60% detachment was achieved in both activated and non-activated T cells. 
The inability to achieve complete release of the coupled liposomes is likely due to both 
nonspecific interactions and the requirement that multiple disulfide bonds need to be broken 
up simultaneously. As represented in Figure S4, the confocal images show that the partial 
detachment is not due to internalization of the particles, as it can be observed that the 
refractory particles are still located at the surface of the T cells. In addition, previous reports 
on the internalization of particles in T cells agree that the endocytic uptake of NPs in this cell 
type is rather exceptional. Nevertheless, we could show that the liposomes do not tend to 
aggregate upon release from the cell surface as only a minor increase in the liposome diameter 
was observed compared to the original liposomes. The latter is of key importance for the 
subsequent internalization of the released particles in the target tumor cells.  
In general, the use of cells as carriers was inspired by the observation that certain pathogens 
can evade the immune system by attaching themselves to the surface of red blood cells [46-
48]. These observations paved the way for NP cell-mediated delivery, in which the carriers 
might prevent the clearance of the particles upon intravenous injection and enhance the 
accumulation of NPs in inaccessible regions [49-51]. Different coupling strategies have been 
assessed such as passive adsorption and ligand-receptor interactions, however, the covalent 
linkage of particles to reactive groups that are present at the cellular surface has proven most 
promising in terms of coupling stability [13, 52]. 
To our knowledge, this is the first study that demonstrates the reversible coupling of NPs to 
CTLs. This reversible strategy is of interest to improve the intratumoral delivery of both low 
molecular weight chemotherapeutic drugs but is of particular interest for membrane-
impermeable macromolecular therapeutics, like small interfering RNA (siRNA). While the 
nanocarriers should prevent siRNA degradation in the systemic circulation and fast renal 
clearance, the T cell-mediated delivery might actively enhance its accumulation in the tumor 
site. Triggered detachment of the nanomedicines from the carrier cell surface should enable 
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their subsequent internalization by target cells in the tumor and intracellular delivery of the 
therapeutic payload. In light of this concept, we developed a lipid-polymer nanocomposite 
that allows high siRNA loading in the polymer core and is coated with a PDP-modified lipid 
shell. The latter improves both NP stability and at the same time enables the functionalization 
of the NP surface with a PDP linker lipid to allow reducible binding to CD8+ T cells. Genetic 
interference using siRNAs to target genes involved in cancer cell proliferation, survival, 
angiogenesis, and metastasis has been widely investigated [53, 54]. In the context of cancer 
immunotherapy, key regulators of the immunosuppressive pathways in immune cells of the 
tumor microenvironment can also be envisioned. Moreover, applying siRNA as a therapeutic 
agent to induce sequence-specific silencing of disease-related target genes can avoid off-target 
toxicity to healthy cells. The latter is also of particular importance to avoid side effects of the 
released drug onto the CTL carrier. Although the T-cell mediated NP delivery concept can be 
expanded to lipid-based NPs loaded with chemotherapeutics, within the latter approach it is 
imperative to also consider the possible toxic effects of the chemotherapeutic agent onto the 
carrier cells itself.  
Although the injection of tumor-specific T cells as a therapy already showed impressive 
clinical outcomes, the limited number of patients that can be cured with this therapy is often 
related to the immunosuppressive role of the tumor microenvironment, the intra-tumor 
heterogeneity, and loss of antigens to which the adoptive T cell therapy was engineered [55, 
56].  
These factors jointly underscore the need to investigate combinatorial anti-cancer strategies 
leading to synergistic effects as was suggested here via the enhancement of the efficacy of the 
T cell therapy by the concurrent delivery of siRNA-loaded NPs, acting against adoptive T cell 
therapy-refractory tumor cells and/or immunosuppressive cells. Future research will be 
focused on the in vivo evaluation of this novel concept in validated models of adoptive T cell 
therapy.   
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5 Conclusion 
A novel technique was developed to reversibly attach lipid-based NPs to the surface of CTLs. 
This study revealed the importance of both the lipid composition and the cell activation status 
on the loading efficiency of the CD8+ T cells. Furthermore, it was shown that the presence of 
NPs on the cell surface does not affect the in vitro evaluated cellular functions such as 
proliferation and cytolytic activity. Cell-mediated delivery of NPs to tumor tissues is 
promising in terms of overcoming barriers that intravenously injected free NPs encounter on 
their way to the tumor tissue. Additionally, a reversible coupling strategy is of importance to 
allow subsequent internalization of the released NPs by tumor target cells, especially for the 
delivery of membrane-impermeable macromolecular therapeutics that require cytosolic 
delivery into tumor cells to be functional. To that end, we demonstrated the triggered release 
of disulfide-coupled liposomes from the T cell surface via glutathione, mimicking the 
thiolytic tumor microenvironment. Exploiting this optimized coupling strategy, we 
demonstrated the anchoring of siRNA-loaded lipid-coated nanogels to the surface of activated 
CD8+ T cells.  
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Figure S1. Binding of DiD-labeled liposomes with 50 wt% PDP lipids to non-activated 
CD8+ T cells as a function of total lipid concentrations. CD8+ T cells were incubated with 
increasing amounts of liposomes, composed of 50 wt% PE-PDP, 3 wt% DiD and 47 wt% 
DOPC lipids. Data represent DiD mean fluorescence intensity (MFI) per cell ± SD (n = 2). 
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Figure S2. Size of CD8+ T cells in function of activation time. (A) Mean forward scatter 
(FSC) ± SD of activated CD8+ T cells as a function of activation time (n = 1 for non-activated 
cells and n = 3 for activated cells). FSC and SSC plots of cells activated during (B) 7, (C) 10, 
(D) 12, and (E) 14 days. Data represent viable cells that were selected based on a SYTOX® 
green dead cell stain. 
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Figure S3. Confocal images of liposomes attached to CD8+ T cells incubated with or 
without glutathione. Cells were first incubated with DiD-labeled liposomes, followed by the 
incubation of the cells with phosphate buffered saline (PBS) supplemented with 5% fetal 
bovine serum (FBS) (A), and with 2 mg ml-1 glutathione in PBS supplemented with 5% FBS 
(B). The left panel shows overlay images and the right panel DiD fluorescence (scale bar = 50 
µm). 
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Figure S4. Co-culture of (liposome-loaded) OT-I CD8+ T cells with E.G7-OVA target 
cells and EL4 control cells. (A) Schematic representation of co-culturing OT-I CD8+ T cells 
with EL4 control cells and E.G7-OVA target cells. E.G7-OVA and EL4 cells were labeled 
with a high and low CFSE concentration, respectively. Both cell types were mixed in equal 
amounts and incubated for 4h at 37 °C with OT-I CD8+ T cells. (B) Histograms of low CFSE-
labeled EL4 cells, high CFSE-labeled E.G7-OVA cells, and a co-culture of EL4 and E.G7-
OVA cells without T cells.  
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Figure S5. Percentage viable E.G7-OVA cells after the incubation with OT-I CD8+ T 
cells. EL4 and E.G7-OVA cells were first mixed in equal amounts, followed by the 4h 
incubation at 37 °C without OT-I T cells, with non-loaded T cells, and with liposome-loaded 
T cells (5 mg ml-1 lipids) in a (A) 1:1 and (B) 1:20 effector:target (E:T) ratio. The E.G7-OVA 
and EL4 population was distinguished by their different CFSE fluorescence intensity via flow 
cytometry. The % E.G7-OVA cells represented here is the E.G7-OVA cell fraction of the total 
population of EL4 and E.G7-OVA cells (n = 3, ns = not significant, *** = p< 0.001).  
 
 
 
